About ANGLO-FRENCH DRUGS & INDUSTRIES LIMITED UNLISTED Unquoted Shares
ANGLO – FRENCH DRUGS & INDUSTRIES LIMITED (AFDIL) is a pharmaceutical company established in 1923 and based in Bengaluru. The company is mainly engaged in the manufacturing of pharmaceutical formulations. Pharmaceutical formulation is a process in which different chemical substances, including the active drug, are mixed with each other to produce a final medicinal product.
Anglo–French Drugs & Industries Limited is one of the most prominent pharmaceutical companies recognized not only in India but also at a global level. Anglo-French Drugs & Industries Limited is the first company to manufacture single vitamin injections and a combination of B-complex vitamins in India.
The company focuses mainly on Vitamins, Sleep inducing agents, Antiepileptics and antioxidants, cold and cough preparations, protein food supplements, antibiotics, anti-inflammatory drugs, digestive enzymes, and calcium supplements.
Anglo–French Drugs & Industries Limited serves around 75,000 medical practitioners in India annually. The company has a well-distributed network of 24 Clearing and Forwarding agents and 1600 stockists. The products of Anglo-French Drugs & Industries Limited are available at over 50,000 stores in India. The company has a presence in 16 countries across Eastern Europe, South East Asia & Africa.
Equity shares of Anglo–French Drugs & Industries Limited are listed on the Metropolitan Stock Exchange of India (MSEI).
INCORPORATION DETAILS
|
CIN |
L24230KA1923PLC010205 |
|
Registration Date |
01 February 1923 |
|
Category/Sub-category of the Company |
Company limited by shares |
|
Address of the Registered office and contact details |
No.41, 3rd Cross, V Block, SSI Area, Rajajinagar, Bengaluru – 560010, Karnataka, India Tel No. 080-2315 6757 |
|
Name, Address, and Contact Details of Registrar and Transfer Agent, if any |
Canbank Computer Services Limited, J.P. Royale, 1st Floor, #218, 2nd Main Sampige Road, Malleswaram, Bengaluru 560 003 Tel No.080-23469661/62 |
PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY
|
Name and Description of main products/services |
NIC Code of the product/service |
% to the total turnover of the Company |
|
Manufacturing of Pharmaceutical Formulations |
21002 |
100% |
BOARD OF DIRECTORS
Mr. Abhay Kanoria (Chairman & Managing Director)
Mr. Uddhav Kanoria (President & Whole-time Director)
Mr. Nirbhay Kanoria (Whole-time Director)
Mr. Sanatkumar Manjunath Shirali (Independent Director)
Mr. NalagathAhmedali (Independent Director)
Mrs. Neha Gada (Independent Director)
Mr. Shashikant N More (Nominee Director)
Dr.Rajeshwar B Smarta (Additional Independent Director)
Mr. Rakesh P Kanyadi (Additional Non-Executive Director)
PARTICULARS OF SUBSIDIARY COMPANIES
|
Name of the Company |
% of shares held |
|
Anglo-French Drugs & Industries Private Limited, Singapore |
100% |
SHAREHOLDING PATTERN
(As of 31-03-2020)
|
S. No. |
Shareholders’ Name |
Number of shares |
% of total Shares of the company |
|
1 |
Binod Kumar Kanoria(HUF) |
200 |
0.017% |
|
2 |
Prabhadevi Kanoria |
3,450 |
0.297% |
|
3 |
Abhay Kanoria |
7,02,205 |
60.405% |
|
4 |
Public Shareholding |
4,56,645 |
39.28% |
|
|
Total |
11,62,500 |
100 |
INDUSTRY OUTLOOK
Indian Pharmaceutical market ranks as 3rd largest in the world in terms of volume and 14th largest in terms of value. Healthcare has become one of the largest sectors of the Indian economy, in terms of both employment and revenue. India is known as the Pharmacy of the world and is the largest provider of generic drugs at a global level. The pharmaceutical industry of India supplies over 50% of global demand for various vaccines, 40% of generic demands in the USA, and 25% of all the medicines in the United Kingdom. Excellent Research & Development, low cost of labor, availability of management and technical personnel, and local equipment’s availability have helped India to manufacture pharma products at a very low cost.
The Indian healthcare market may see a 3 fold jump in terms of value to reach US$ 372 billion by FY 2022. The growth can be attributed to rising income, greater health awareness, increased precedence of lifestyle disease, and Indian prominence in making medicinal products for the treatment of COVID 19. India aims to achieve vaccination for COVID-19 of 30 Crore people in the next few months.
Export of Pharmaceuticals products from India stood at US$ 16.8 billion in FY 2020 and US$ 2.07 billion in the month of October 2020. In the first 3 quarters of FY 2021, India exported pharmaceuticals worth US$ 15.86 billion. India supplied around 45 tons and 400 million tablets of hydroxychloroquine to around 114 countries globally to treat the covid patients in the initial stage of the covid-19 pandemic. Exports in FY 2021 of Indian pharma products are expected to cross US$ 24 billion, increasing by over 16% when compared to FY 2020.
After the onset of COVID-19, the Indian pharmaceutical sector became the busiest sector in the Indian economy. The pandemic proved to be a boon in disguise for the Indian pharmaceutical sector.
KEY FINANCIALS OF ANGLO-FRENCH DRUGS & INDUSTRIES LIMITED (In Rs. Lakhs)
|
PARTICULARS |
2021 |
2020 |
2019 |
2018 |
|
Revenue from Operations |
15,378 |
13,018 |
12,914 |
11,140 |
|
EBITDA |
1,636 |
1,238 |
694 |
-784 |
|
EBITDA margin |
10.64% |
9.51% |
5.37% |
-7.04% |
|
Finance Cost |
2,722 |
617 |
676 |
429 |
|
Depreciation |
529 |
254 |
173 |
179 |
|
Other Income |
102 |
155 |
70 |
101 |
|
Profit Before exceptional items and tax |
963 |
522 |
-85 |
-1,291 |
|
Exceptional items |
0 |
-156 |
0 |
0 |
|
Total Tax |
212 |
55 |
0 |
-167 |
|
Profit After Tax (PAT) |
751 |
311 |
-85 |
-1,124 |
|
PAT margin |
4.88% |
2.36% |
-0.65% |
-10.00% |
|
EPS |
61.94 |
26.72 |
-7.31 |
-96.69 |
BALANCE SHEET OF ANGLO-FRENCH DRUGS & INDUSTRIES LIMITED(In Rs. Lakhs)
|
PARTICULARS |
31st March 2021 |
31st March 2020 |
31st March 2019 |
|
ASSETS |
|||
|
NON CURRENT ASSETS |
|||
|
Tangible assets |
1,358 |
1,527 |
1,475 |
|
Intangible assets |
3 |
4 |
5 |
|
Financial assets |
47 |
117 |
109 |
|
Other non-current assets |
9 |
7 |
27 |
|
TOTAL NON-CURRENT ASSETS |
1,417 |
1,655 |
1,616 |
|
CURRENT ASSETS |
|||
|
Inventories |
3,667 |
4,279 |
3,981 |
|
Trade receivables |
3,626 |
2,581 |
2,950 |
|
Cash and Cash Equivalents |
122 |
64 |
87 |
|
Other current financial assets |
184 |
91 |
88 |
|
Tax assets |
0 |
41 |
86 |
|
Other current assets |
461 |
636 |
565 |
|
TOTAL CURRENT ASSETS |
8,060 |
7,692 |
7,757 |
|
TOTAL ASSETS |
9,477 |
9,347 |
9,373 |
|
EQUITY AND LIABILITIES |
|||
|
EQUITY |
|||
|
Equity share capital |
129 |
116 |
116 |
|
Other Equity |
1,487 |
535 |
279 |
|
TOTAL EQUITY |
1,607 |
651 |
395 |
|
LIABILITIES |
|||
|
NON CURRENT LIABILITIES |
|||
|
Borrowings |
1,647 |
927 |
734 |
|
Other financial liabilities |
311 |
311 |
309 |
|
Employee benefit obligations |
106 |
115 |
105 |
|
Tax Liabilities |
38 |
0 |
0 |
|
TOTAL NON-CURRENT LIABILITIES |
2,102 |
1,353 |
1,148 |
|
CURRENT LIABILITIES |
|||
|
Borrowings |
2,324 |
3,073 |
3,797 |
|
Trade payables |
2,256 |
2,865 |
2,564 |
|
Other financial liabilities |
248 |
627 |
997 |
|
Employee benefits obligations |
58 |
46 |
43 |
|
Current tax liabilities |
34 |
0 |
0 |
|
Other current liabilities |
848 |
733 |
429 |
|
TOTAL CURRENT LIABILITIES |
5,768 |
7,344 |
7,830 |
|
TOTAL LIABILITIES |
7,870 |
8,697 |
8,978 |
|
TOTAL EQUITY AND LIABILITIES |
9,477 |
9,347 |
9,373 |
DIVIDEND HISTORY
|
Particulars |
2020 |
2019 |
2018 |
|
Dividend (final + interim) (In Rs.) |
Nil |
Nil |
Nil |
|
Retained Earnings (Consolidated) (In Rs. Lakhs) |
-123 |
-434 |
-337 |
PERFORMANCE OF THE COMPANY
Revenue from Operations of the company in FY 2021 was Rs.15,378 Lakhs, as against Rs.13,018 Lakhs in FY 2020. Revenue from the Operations of the company increased by just Rs. 2,360 Lakhs, which is about an 18% increase.
EBITDA of the company increased significantly by 32.15% from Rs. 1,238 Lakhs in FY 2020 to Rs. 1,636 Lakhs in FY 2021. EBITDA margins improved from 9.51% in FY 2020 to 10.64% in FY 2021.
In FY 2020, the company made a profit of Rs.311 Lakhs. In FY 2021 the company made a profit of Rs.751 Lakhs, i.e. an increase of 141.48%
The Current Ratio of the company as of 31st March 2021 was 1.40. The debt-to-equity ratio of the company as of 31st March 2021 was 2.47.
The book value per share of the company as of 31st March 2021 stood at Rs.138.24.
Anglo-French Drugs & Industries Limited has not given any dividends for the past 3 years.
During FY 2020, the Company launched two new products in the respiratory segment and one in the nutraceutical segment.
